Related Experiment Video
Updated: Dec 1, 2025

Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles
Published on: November 1, 2017
Deformable liposomal codelivery of vorinostat and simvastatin promotes antitumor responses through remodeling tumor
1State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 501 Haike Rd, Shanghai 201203, China. yzhuang@simm.ac.cn.
Abstract:
The tumor microenvironment (TME) and its major component tumor-associated macrophages (TAM) play a pivotal role in the development of non-small cell lung cancer (NSCLC). An epigenetic drug-based combinatory therapeutic strategy was proposed and a deformable liposome system (D-Lipo) was developed for vorinostat and simvastatin codelivery for remodeling the TME. The application of deformable liposomes in systemic cancer drug delivery has been underexplored and its potential in cancer therapy is largely unknown. This work revealed that D-Lipo exhibited an enhanced intratumor infiltration ability. The proposed therapeutic strategy was characterized by a chemo-free regimen and TME remodeling function. D-Lipo efficiently inhibited the growth of the xenografted lung tumor. The anti-tumor mechanisms involved the repolarization of TAM from the M2 to M1 phenotype, anti-angiogenesis, and the consequent TME remodeling. As a result, the amounts of the anti-tumor M1 macrophages and the cytotoxic CD8+ T cells increased, while the amounts of the pro-tumor M2 macrophages and regulatory T cells (Tregs) reduced. It provides a promising avenue for epigenetic drug-based combination therapy for treating solid tumors.
Insights
This study developed a novel deformable liposome system for delivering epigenetic drugs to remodel the tumor microenvironment in non-small cell lung cancer. The treatment effectively inhibited tumor growth by reprogramming macrophages and enhancing anti-tumor immunity.
Area of Science:
- Oncology
- Nanomedicine
- Immunology
Background:
- The tumor microenvironment (TME) and tumor-associated macrophages (TAM) are critical in non-small cell lung cancer (NSCLC) progression.
- Epigenetic therapies offer potential for TME remodeling, but effective drug delivery remains a challenge.
Purpose of the Study:
- To develop a deformable liposome (D-Lipo) system for codelivering vorinostat and simvastatin.
- To investigate the efficacy of D-Lipo in a chemo-free therapeutic strategy for NSCLC by remodeling the TME.
Main Methods:
- Formulation of deformable liposomes for dual drug delivery.
- Evaluation of D-Lipo's intratumor infiltration and anti-tumor efficacy in xenografted lung tumors.
- Analysis of immune cell populations (TAMs, CD8+ T cells, Tregs) and angiogenesis within the TME.
Main Results:
- D-Lipo demonstrated enhanced intratumor infiltration and inhibited xenografted lung tumor growth.
- The therapy successfully repolarized TAMs from M2 (pro-tumor) to M1 (anti-tumor) phenotype.
- Significant reduction in pro-tumor M2 macrophages and regulatory T cells (Tregs), alongside an increase in anti-tumor M1 macrophages and CD8+ T cells, indicating TME remodeling and anti-angiogenesis.
Conclusions:
- Deformable liposomes provide an effective platform for epigenetic drug codelivery, enabling chemo-free cancer therapy.
- This strategy shows promise for remodeling the tumor microenvironment and enhancing anti-tumor immunity in solid tumors like NSCLC.
Related Concept Videos
Tumor Immunotherapy
The Tumor Microenvironment
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Targeted Cancer Therapies
There are several types of targeted therapies against...
Bioavailability Enhancement: Drug Permeability Enhancement
Lipid-Lowering Drugs: Statins and Miscellaneous Agents

